



an Open Access Journal by MDPI

Extracellular Vesicle for Tumor Targeting Delivery System and Tumor Immunotherapy

Guest Editors:

Dr. Ke Tang

Tongji Medical College,
Huazhong University of Science &
Technology, Wuhan 430074,
China

Prof. Dr. Honglin Jin

College of Biomedicine and
Health, Huazhong Agricultural
University, Wuhan 430070, China

Deadline for manuscript
submissions:

closed (16 December 2022)

Message from the Guest Editors

Since Dr. Peter Wolf first proposed "platelet dust" in 1967, extracellular vesicles (EVs) have been gradually known by us. EVs (including plasma membrane derived microparticles and endosomal derived exosomes) play an important role on information exchange between cells through contained protein, lipids and RNA or DNA. In recent years, due to its histocompatibility, natural carrier characteristics and its removability, EV has been widely used in tumor targeted drug delivery and immunotherapy. This special issue mainly collects research papers, reviews or comments on extracellular vesicles in drug delivery and immunotherapy on tumor, as well as related bioengineering and clinical translational study.



mdpi.com/si/111356

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical
Engineering, Texas A&M
University, College Station, TX
77843, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

Journal Rank: JCR - Q2 (*Engineering, Biomedical*)

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2024).

Contact Us

Bioengineering Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/bioengineering
bioengineering@mdpi.com
[X@Bioeng_MDPI](https://twitter.com/Bioeng_MDPI)